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Abstract
Background: In Sudan, chloroquine (CQ) remains the most frequently used drug for falciparum
malaria for more than 40 years. The change to artemisinin-based combination therapy (ACT) was
initiated in 2004 using the co-blister of artesunate + sulfadoxine/pyrimethamine (AS+SP) and
artemether + lumefantrine (ART+LUM), as first- and second-line, respectively. This article
describes the evidence-base, the process for policy change and it reflects the experience of one
year implementation. Relevant published and unpublished documents were reviewed. Data and
information obtained were compiled into a structured format.
Case description: Sudan has used evidence to update its malaria treatment to ACTs. The country
moved without interim period and proceeded with country-wide implementation instead of a
phased introduction of the new policy. The involvement of care providers and key stakeholders in
a form of a technical advisory committee is considered the key issue in the process. Development
and distribution of guidelines, training of care providers, communication to the public and provision
of drugs were given great consideration. To ensure presence of high quality drugs, a system for
post-marketing drugs surveillance was established. Currently, ACTs are chargeable and chiefly
available in urban areas. With the input from the Global Fund to fight AIDs, Tuberculosis and
Malaria, AS+SP is now available free of charge in 10 states.
Conclusion: Implementation of the new policy is affected by the limited availability of the drugs,
their high cost and limited pre-qualified manufacturers. Substantial funding needs to be mobilized
by all partners to increase patients' access for this life-saving intervention.
Background
Malaria is a leading cause of morbidity and mortality in
Sudan resulting in an estimated 7.5 million cases and
35,000 deaths annually [1]. Possible contributing factors
leading to this grave situation include floods, draught,
famine, widely extended irrigated schemes without
enough consideration to health component and popula-
tion movement (internal displacement and influx of refu-
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gees). The situation may be further aggravated by
insecticide resistance [2] and the spread of Plasmodium fal-
ciparum resistant strains [3].
Chloroquine (CQ) has been the most frequently used
drug in Sudan as a first line for years. The drug was avail-
able through public, private and not-for-profit pharma-
cies. A recent study showed that 85.6% of severe malaria
patients admitted to five hospitals in central Sudan
received CQ before hospitalization [4] and that CQ was
also the commonly prescribed drug by health care provid-
ers [5].
In Sudan, malaria control was based for decades on vector
control, through spraying with insecticides. In the late
1990s, great efforts were directed to improve malaria case
management and this was included in the development of
the Roll Back Malaria (RBM) strategic plan in 2001. Case
management requires the provision of prompt, effective
and safe treatment to malaria cases [6]. Using the results
of research on resistance to CQ, Sudanese policy-makers
updated their national malaria treatment guidelines in
2004 to artemisinin-based combination therapy (ACTs),
both as first- and second-line treatment for the manage-
ment of uncomplicated falciparum malaria. This case
study aims to provide the evidence-basis and to describe
the process for change and the experience of one year
implementation.
Information and data tackled here were collected using
two methods. Published antimalarial drugs efficacy stud-
ies carried out in Sudan between 1975 and 2005 were
identified through searches of on-line databases (PubMed
Medline – using the address: http://
www4.ncbi.nlm.nih.gov/PubMed). Published data not
on-line were also identified and copies from authors were
collected when possible. Official unpublished documents
related to the drug policy issue, procurement or manufac-
turing of the anti-malarial drugs were obtained from the
National Malaria Control Programme (NMCP), General
Directorate of Pharmacy (GDP) and the Central Medical
Supply (CMS). Data of regional and national conferences
or meetings were also obtained in soft or hard copies
either directly from the organizers or from websites.
Case description
Efficacy studies supporting change from CQ to ACT
From 1975 to 2005, many drug efficacy studies were car-
ried out in Sudan, several published in international and
national scientific journals. Table 1 presents the propor-
tion of in vivo parasitological treatment failure for various
antimalarials used as monotherapy or combination ther-
apy for the treatment of uncomplicated falciparum
malaria in Sudan. Since the 1970s, CQ resistance has been
documented and has since increased and spread all over
Sudan [7-15]. Limited studies of sulfadoxine-pyrimeth-
amine (SP) efficacy were only carried out in 2000,
Table 1: Susceptibility of P. falciparum to antimalarials in Sudan, 1975–2005.
Period Drugs tested Regions Protocol used follow-up (days) Failure rate (%) References number
1975–97 CQ central Standard WHO in-vivo test 7–28 0.8–25.0 7, 10
eastern 43.0–48.0 8, 9
1998–03 CQ central WHO 1996 14–28 25.0–75.0 11, 12
eastern WHO 1996 28 76.9 13
southern WHO 1996, EANMAT 1999 14–28 11.5–93.9 14, 15
north Sudan WHO 1996 14 32.0–70.0 UPD
SP eastern WHO 1996 28 0.0–19.4 16, 17
southern WHO 1996, EANMAT 1999 14–28 0.0–69.9 15, 14
north Sudan WHO 1996 28 1.3–7.8 UPD
AQ southern WHO 1996, EANMAT 1999 14 5.9–25.2 14, 15
MQ eastern WHO 1996 28 7.5 20
Q eastern WHO 1996 28 9.4–10.7 13
CQ+SP eastern WHO 2003 28 2.5–36.0 17, UPD
central WHO 1996 28 15.5–20.0 UPD
AS+SP western WHO 2003 28 8.8 21
southern WHO 2003, 1996 28–42 0.0–0.9 22
central WHO 2003 28 0.0 UPD
AS+AQ western WHO 2003 28 7.3 21
southern WHO 2003, 1996 42 1.0 22
2004–05 AS+SP eastern WHO 2003 28 0.0–0.7 18, 23
southern WHO 2003, 1996 28–42 0.0 23
central WHO 2003 28 0.0 23, 24, UPD
ART+ LUM southern WHO 2003 28 0.0 UPD
central WHO 2003 28 0.0 24
UPD: unpublished dataMalaria Journal 2006, 5:65 http://www.malariajournal.com/content/5/1/65
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although it had been used as a second-line treatment for a
long time [13-18]. Efficacy of combination therapy started
by testing the efficacy of (CQ+SP) combination in four
sites. High level of resistance (15.5 – 36.0%) was deter-
mined in three of them [17]. Results of ACTs studies
started in 2003 and became available (late in 2003 or
early in 2004) for the National Malaria Control Pro-
gramme (NMCP) before publication. The combination of
artesunate plus SP (AS+SP) was tested in 10 areas with no
reported failure in seven of them, <1.0% failure rate in
two and up to 8.8% failure rate in one site [18,21-24].
Artesunate plus amodiaquine (AS+AQ) was tested in
southern and western Sudan with a failure rate of 1.0 to
7.3% respectively [20,22]. Artemether plus lumefantrine
(ART+LUM) was tested in two sites with no reported fail-
ure rate [24].
Process for change
In 1998, the NMCP organized an important workshop on
malaria treatment to develop national treatment guide-
lines, with CQ as first-line. In 2001, the NMCP estab-
lished a technical advisory committee (TAC) to assist the
Federal Ministry of Health (FMOH) in decisions related to
first-line treatment of malaria, in view of available data
about CQ resistance. The TAC is constituted of 40 mem-
bers, representing clinicians, pharmacists, policy makers,
UN agencies and academic and research institutes with
support, from time to time, from WHO consultants. The
TAC refused the suggestion from the NMCP to change the
policy from CQ to CQ+SP because of the lack of evidence.
Secondly, the decision to change from CQ to ACTs was
taken based on national and international evidence. An
important landmark in the process of change has been the
"treatment options against malaria in Sudan" conference
initiated by Médecins Sans Frontières (MSF) and arranged
jointly between FMOH, WHO and MSF in October 2003.
The conference reviewed the most recent evidence and the
experience of other countries and it generated recommen-
dations, which are reflected in Figure 1. Immediately after
the conference, a small committee (members of TAC who
participated in the conference) was nominated by the
NMCP to select the drugs to be used as first- and second-
lines in Sudan. The work of this committee then reviewed
Treatment options against malaria in Sudan" conference conclusions and recommendations Figure 1
Treatment options against malaria in Sudan" conference conclusions and recommendations.
MSF, FMOH and WHO
Treatment options against malaria in Sudan
14-15 October 2003, Khartoum, Sudan
CONFERENCE CONCLUSIONS AND RECOMMENDATIONS
After substantial discussion, the conference participants agreed that it is the time for
combination therapy. The suitable options for Sudan will be finalized by the
Technical Advisory Committee of the Federal Ministry of Health. The following
options will be considered: CQ+SP / AS+SP / AS+AQ / SP+AQ / Coartem®.
The participants also agreed that advances in the implementation of combination
therapy should be made by the next rainy season.Malaria Journal 2006, 5:65 http://www.malariajournal.com/content/5/1/65
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and approved by the TAC retaining AS+SP as first-line and
ART+LUM as second-line treatment.
The policy was then endorsed by Undersecretary of
Health, who communicated the new malaria treatment
policy to all concerned bodies of FMOH (General Direc-
torate of Pharmacy, Central Medical Supply, Integrated
Management of Childhood Illnesses programme, etc) and
to major partners agencies (WHO, UNICEF, MSF, etc).
Subsequently, the national guidelines for treatment of
malaria developed by NMCP staff, endorsed by the TAC,
revised by local experts and WHO consultants and edited.
Further, the guideline was piloted in 25 sites (in five
states) to obtain feedback from providers. Remarks were
taken into consideration when the final version was devel-
oped.
Implementation of change
The NMCP worked simultaneously on many issues
related to the implementation of the new treatment policy
(Figure 2). The new guidelines were summarized as book-
lets and wall charts, both in Arabic and in English, and
enough copies were printed and distributed at different
levels with support from FMOH, WHO, NGOs and pri-
vate companies. Orientation sessions aiming to launch
the new treatment guidelines were carried out at state cap-
itals for physicians, pharmacists, Ministry of Health Heads
of Departments and policymakers in 20 states. Each ses-
sion (2–3 hours) consisted of a formal presentation, the
distribution of guidelines, an open discussion and show-
ing samples of the recommended drugs. This was fol-
lowed by a 3-day training session for medical doctors,
medical assistants, pharmacists, assistant pharmacists and
community health workers. The training, which is still
going on, was started by the training of trainers assigned
by different states using a training manual. These trainers
arranged for training in their respective states with the
assistants from NMCP staff and senior physicians. The
GDP announced through its website for companies to
submit for registration according to pharmaceutical regu-
lations and specifications stated in the treatment guide-
lines (eg a co-blister of AS and SP). The NMCP also
addressed local manufacturers and encouraged them to
change from CQ to the new drugs. A co-blister of AS+SP
from two of them is becoming available for assessment by
GDP in October 2005. One of the assessed products has
been registered and distributed and the registration of the
other is bending on fulfilment of certain technical and
administrative requirements. A system for drug post-mar-
keting surveillance was arranged in collaboration with the
national drug laboratory for quality assurance. Official
inspector (pharmacist from National Malaria Control
Programme – Sudan) coordinating collection from sev-
eral states and was responsible for sample coding and
transport to the National Drug Quality Control Labora-
tory at Khartoum for analysis. Samples were analyzed
according to the international pharmacopoeia and Chi-
nese pharmacopoeia to assess the quality of the products.
International pharmacopoeia is the first choice for work
in the laboratory but Chinese pharmacopoeia was used
for dissolution test as that test has not been developed yet
in the international pharmacopoeia.
The experience of other countries was taken into consider-
ation and the Zanzibar experience with the use of AS+AQ
was shared through a visit (arranged by the Malaria Con-
sortium) of the Zanzibar RBM coordinator to Sudan.
Communicating the change to the public was imple-
mented progressively. Broadcasting messages about
malaria treatment and ACTs through national radio was
implemented since September 2005. The communication
programme consists of four messages per day to be deliv-
ered for two weeks, followed by a break for one week and
then the message is delivered again for two weeks, and so
on. This was supported by WHO and the National Broad-
casting Corporation. The forecasting is targeting the best
time for maximal audience.
What about chloroquine?
The plan is for CQ to be phased out within two years (Fig-
ure 3). CQ is widely available, cheap, providers and care-
givers still rely on it. On the other hand, the availability of
the new recommended drugs is still limited and they are
not affordable. In January 2005, to promote phasing out,
the GDP circulated a letter to manufacturers and import-
ers of CQ to reduce their quantities by 40%. By January
2006, the manufacturing and importation of new CQ in
form of tablets and vials was stopped completely. This was
initiated by a letter from NMCP to GDP which in turn
informed both the manufacturers and importers of CQ in
addition to related authorities. Still one can get CQ from
the circulating drugs in the market.
Experience of one year implementation
As regards to first-line treatment (AS+SP), four companies
have so far registered their products in Sudan. All of them
produce AS+SP as co-blister and started distribution in the
private sector. In addition, a single manufacturer has reg-
istered ART+LUM and another artesunate suppositories.
Two drug factories started the process of local manufactur-
ing of AS+SP and the product of one of them is becoming
available at the drugs distribution outlets. The new recom-
mended medicines have been available through public,
NGOs and private sectors since August 2004. The total
amount of AS+SP strips and of ART+LUM tablets procured
and distributed by all sectors, from August 2004 to Octo-
ber 2005, was 4,095,000 and 495,000, respectively. The
fund used for procurement of AS+SP came from Central
Medical Supply (69.0%), private companies (23.4%) and
UN agencies and NGOs (7.6%). The coverage with ACTsMalaria Journal 2006, 5:65 http://www.malariajournal.com/content/5/1/65
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is expected to increase with the additional input from the
Global Fund to fight AIDS, Tuberculosis and Malaria
(GFATM). Treatment of malaria in Sudan at public sector
level is not free and a system of full cost recovery has been
in operation since the early 1990s, as part of the revolving
drug fund (RDF). The retailed price of the drug, include
Key activities in the processing of changing from CQ to ACTs Figure 2
Key activities in the processing of changing from CQ to ACTs.
Ten key activities
• Establish technical advisory committee; be keen to involve the members and
provide them with necessary tools…
• Provide up-to-date efficacy data covering all possible options to facilitate
decision…
• Endorse the new treatment policy including informing the various
stakeholders…
• Develop user-friendly guidelines, print and distribute in suitable form…
• Orient senior care-providers and arrange to train all health workers…
• Start drug registration early, encourage procurement by public, private and
voluntary sectors…address local manufacturers …
• Address financial issues including deletion of taxes and tariff…
• Start phasing out CQ…
• Inform the public and the media…
• Establish post-marketing drugs surveillance…
It is not mandatory to follow the sequence always…more than one activity can be
done at a time…Malaria Journal 2006, 5:65 http://www.malariajournal.com/content/5/1/65
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the known international cost in addition to 62% (this
include 27% as taxes and 35% as private benefit) when
the drug has been procured and distributed by the private
sector. Thus >90% of the money needed for the procure-
ment is provided by malaria patients. The price for AS+SP
ranged between $2.4 and $4.4 per adult treatment and
between $2.0 and $3.2 per child. One tablets of
ART+LUM cost the patient $0.4 and the cost varies
between $2.4 and $9.6 per treatment, respectively for the
youngest child and for an adult. Both drugs are available
at urban setting from which medical assistants and senior
nurses working at dispensaries in rural areas can get the
drugs. A system for post-marketing drug surveillance was
established in collaboration with the GDP. The case man-
agement staff of the NMCP collects the drugs from differ-
ent part of the Sudan and the drug quality laboratory at
GDP conducts the necessary tests. Two rounds targeting
AS+SP have been completed so far.
Discussion
Evidence for change
Confirmed cases of CQ resistance in Sudan were first
reported in 1978 [7]. The first evidence to support the
change from CQ to alternative drugs was compiled and
Phasing out of CQ as response to increasing use of ACTs over 2 years (hypothetical figures) Figure 3
Phasing out of CQ as response to increasing use of ACTs over 2 years (hypothetical figures). 
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presented at the workshop on malaria treatment in Khar-
toum in 1998. As a result, malaria treatment guidelines
were developed to promote the rational use of antimalar-
ials, including CQ and SP, with emphasis on regular mon-
itoring of the efficacy of CQ. From 1998 to 2003,
treatment guidelines were developed and distributed all
over the country, training targeting different providers was
carried out and sentinel sites to monitor CQ and SP effi-
cacy were established with support from WHO. Later in
2001, a TAC was formed with regular meetings. As in
many countries in Africa [25-29], Sudan has used evi-
dence to update its malaria treatment from CQ to ACTs.
This was recognized by the Council on Health Research
for Development – COHRED [30]. By the end of 2003,
overwhelming evidence showed that CQ was no longer
suitable for uncomplicated malaria treatment in Sudan
[3,12,14,15,31], Furthermore, SP treatment failure ranged
between 1.9% and 7.8%. Recent studies showed, CQ+SP
treatment failure rate ranging between 2.5 to 36.0% [17]
in contrast to high response rate to ACTs – (AS+SP and
AS+AQ) [21,22]. In addition, researchers from NMCP and
other institutes provided supportive data after the launch-
ing of the new treatment guidelines [18,21,23,24]. Sudan
moved from CQ to ACTs without an interim period, in
contrast to other countries in Africa [28,29,32,33]. Sudan
also proceeded with country-wide implementation
instead of a phased introduction of the new policy.
Despite the evidence of CQ resistance in many WHO East-
ern Mediterranean Region [3], Sudan was the first country
in the region to shift to ACTs.
Factors affecting the decision
Changing drug policy is complex. Limiting factors are
high cost, limited knowledge and lack of public awareness
on the effectiveness and safety of ACTs in addition to
operational issues [34-36]. Changing from CQ in particu-
lar is challenging as stated by other authors [29]. CQ is
widely available, easy to use and cheap. These factors
delayed the decision in Sudan despite the fact that all the
TAC members were convinced of the necessity to change
from CQ to an alternative drug very early in 2002. Never-
theless, Sudan has changed its malaria treatment protocol
in 2004 to provide artemisinin-based combination ther-
apy as first-line (AS+SP) and second-line (ART+LUM)
treatment. The conference arranged by MSF-France (treat-
ment options against malaria in Sudan) and the technical
support from WHO played major role in solving this con-
cern. TAC members recognized the high benefits of pro-
viding effective drugs to those who are suffering, despite
the high costs of the drugs. ACTs may cost up to 20 times
more than the currently available antimalarials [36], but
considering the factors that determine the effectiveness of
malaria treatment policy [35], the direct cost of imple-
menting ACTs (AS+AQ) for confirmed malaria cases
could be up to 53% less expensive than using CQ and Q
for clinically diagnosed cases as documented in Senegal
[37]. Several studies have documented that continued use
of CQ is contributing to increase hospital attendance and
admission, malaria-associated mortality [38,39], severe
malarial anaemia [39], and malaria case fatality rate may
decreased with the provision of effective treatment [40]. A
recent study in KwaZulu Natal, South Africa, also docu-
mented that implementation of ACTs reduced total
expenditure on malaria services [41]. Some of these fac-
tors led to the decision of phasing out of CQ rather than
abrupt cessation of monotherapy in order to avoid a sup-
ply shortage while an increasing proportion of people is
being convinced that CQ is no longer the suitable treat-
ment option and new medicine become available.
Challenges to implementation of change
Faced with the dilemma of comparing the newly recom-
mended drugs with CQ, the population prefers drugs
which are cheap, easy to use, readily available and safe for
all age groups [42]. Successful strategies to change behav-
iour need to include the use of rigorous evidence, involv-
ing scientist in the decision-making process, focusing on
communication, receiving support from credible partners
(WHO), utilizing regional approaches rather than focus-
ing solely on the home country, and a better understand-
ing of the political system [43]. In Sudan, it was decided
to have the first-line as co-blister rather than each drug
separately. Negative aspects of monotherapy, which may
affect prescriber's and consumer's practice, include: the
provider not prescribing both drugs, the patient not tak-
ing both drugs because of the price or not accepting to use
both drugs. Policy makers at GDP were highly concerned
about the availability of ACTs and their stability in hot
wheather, such as exists in Sudan. As no company at time
of launching the new policy was qualified by WHO to
provide co-blister of AS+SP, the registration of the recom-
mended first-line drug was difficult and further compli-
cated by results of post-marketing surveillance of some
company products which showed sub-standard stability.
A recent household survey carried out in 10 states to pro-
vide base-line data for GFATM support showed limited
availability of ACTs and hence treatment of malaria still
relied on CQ (65.6%). The treatment with ACTs was
reported to be only 10.5% on average. Higher rates were
seen in urban areas (18.1%) and the lowest in rural areas
(5.6%). This is similar to the Zambian experience, even if
ART+LUM was made available free-of-charge in Zambia
[44].
In Sudan, drugs are available to patients through the RDF
in the public sector as well as in the private and NGOs sec-
tors. Drugs provided through the public sector were hav-
ing relatively low price compared with the private sector
(almost 30–50% lower). The difference in price is due to
bulk purchase and exemptions from high taxes and tariffMalaria Journal 2006, 5:65 http://www.malariajournal.com/content/5/1/65
Page 8 of 9
(page number not for citation purposes)
(almost 27%). High cost was found to delay treatment-
seeking in Sudan [4,45]. Therefore, the public sector has
to take the lead in ensuring access and the NMCP should
develop the strategies recommended to improve the
affordability and financing of ACTs [46]. The release of
round-two of GFATM support, in addition to procure-
ment through NGOs and UN agencies, give some hope in
improving availability and affordability, considering that
the estimated cost of ACTs is beyond the country
resources [47]. By January 2006, a total of 995,000 paedi-
atrics doses (50 mg artesunate) and 1,133,000 adult doses
(100 mg artesunate) procured as part of round-two
GFATM. The drug (under the brand name 'ARTECOSPE')
has been distributed into 466 health facilities in 11 states
out of Sudan 25 states free of charge. Unicef agreed to pro-
cure 1400,000 doses to be use in states where the GFATM
is not there.
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